Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

MLYS

Mineralys Therapeutics (MLYS)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MLYS
DataOraFonteTitoloSimboloCompagnia
12/03/202521:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLYSMineralys Therapeutics Inc
12/03/202521:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MLYSMineralys Therapeutics Inc
12/03/202503:20GlobeNewswire Inc.Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common StockNASDAQ:MLYSMineralys Therapeutics Inc
10/03/202521:01GlobeNewswire Inc.Mineralys Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:MLYSMineralys Therapeutics Inc
10/03/202512:00GlobeNewswire Inc.Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
07/03/202522:01GlobeNewswire Inc.Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ETNASDAQ:MLYSMineralys Therapeutics Inc
25/02/202500:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLYSMineralys Therapeutics Inc
14/02/202512:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MLYSMineralys Therapeutics Inc
12/02/202513:00GlobeNewswire Inc.Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
05/02/202522:05GlobeNewswire Inc.Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025NASDAQ:MLYSMineralys Therapeutics Inc
04/02/202514:00GlobeNewswire Inc.Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and AlbuminuriaNASDAQ:MLYSMineralys Therapeutics Inc
08/01/202514:00GlobeNewswire Inc.Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
13/11/202422:27Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MLYSMineralys Therapeutics Inc
12/11/202414:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLYSMineralys Therapeutics Inc
11/11/202422:05GlobeNewswire Inc.Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
05/11/202422:05GlobeNewswire Inc.Mineralys Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:MLYSMineralys Therapeutics Inc
30/10/202413:00GlobeNewswire Inc.Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
22/10/202414:00GlobeNewswire Inc.Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024NASDAQ:MLYSMineralys Therapeutics Inc
25/09/202414:00GlobeNewswire Inc.Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of HypertensionNASDAQ:MLYSMineralys Therapeutics Inc
13/08/202422:05GlobeNewswire Inc.Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
05/08/202422:05GlobeNewswire Inc.Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024NASDAQ:MLYSMineralys Therapeutics Inc
17/06/202422:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MLYSMineralys Therapeutics Inc
14/06/202414:00GlobeNewswire Inc.Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of DirectorsNASDAQ:MLYSMineralys Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
06/05/202414:00GlobeNewswire Inc.Mineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceNASDAQ:MLYSMineralys Therapeutics Inc
02/05/202414:00GlobeNewswire Inc.Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024NASDAQ:MLYSMineralys Therapeutics Inc
21/03/202412:00GlobeNewswire Inc.Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:MLYSMineralys Therapeutics Inc
13/03/202421:05GlobeNewswire Inc.Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024NASDAQ:MLYSMineralys Therapeutics Inc
15/02/202422:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MLYSMineralys Therapeutics Inc
08/02/202414:00GlobeNewswire Inc.Mineralys Therapeutics Announces $120 Million Private Placement FinancingNASDAQ:MLYSMineralys Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MLYS
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network